Zika Vaccines Are Widely Being Developed In Many Research Institute to Combat the Increasing Prevalence of the Virus

 

Zika Vaccines

Vaccination against Zika is the first step toward preventing or controlling the disease. It is important to receive the vaccine during all stages of exposure, including the early postnatal period. Zika vaccines help protect against intrauterine infection and reduce the risk of transmission to the unborn child. It is important to note that the African Zika virus is not associated with congenital malformations.

According to Coherent Market Insights the Zika Vaccines Market Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2022-2028.

As the Zika virus continues to spread throughout the Americas, research into new Zika vaccines is advancing. In September, a phase 1 clinical trial of the DNA vaccine was started in Texas. A phase 2b study will be conducted in multiple sites where ZIKV is endemic. These studies will provide more evidence of the effectiveness of the vaccine in protecting against the disease. In the meantime, there is no known cure for Zika.

Furthermore, human antibodies to ZIKV have been developed in laboratories. Human B-cell immortalization was used to identify the most effective antibodies to block ZIKV infection. The ZIKV-117 mAb was identified as broadly neutralizing and inhibited ZIKV infection in vitro. It recognizes a unique quaternary epitope in the E protein dimer-dimer interface. There is also a bispecific mAb being developed that addresses concerns of antiviral resistance.

A vaccine that protects against Zika is not far away. Researchers are closely monitoring the development of a Zika vaccines to combat the outbreak and are developing an experimental weakened version. However, there are several challenges in developing this vaccine. Despite its potential benefits, the costs and technical challenges may outweigh the benefits. However, there is little doubt that a vaccine can help prevent the disease, which could be fatal in some cases. Recently in January 2022, researchers at Trudeau Institute, Texas Biomedical Research Institute, SNPRC and WRAIR created a Zika vaccine candidate that was found to be effective at preventing the virus passing from mother to fetus in preclinical animal studies.